Rachael Brake

Rachael Brake brings more than 20 years of experience in the biopharmaceutical industry building and leading cross functional teams across basic and applied research, clinical and business development. Dr. Brake joined Abdera from Zephyr AI where she served as chief scientific officer. Previously, Dr. Brake was the chief scientific officer at Corbus Pharmaceuticals where she built and led a research and development team and advanced multiple oncology programs into clinical development. Prior to her work at Corbus, Dr. Brake spent 11 years at Takeda Oncology, most recently as head of U.S. medical affairs, oncology business unit and as vice president, global program leader, oncology therapeutic area. In these roles, Dr. Brake managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action. Prior to joining Takeda, Dr. Brake was a research scientist at Amgen where she held increasing levels of responsibility culminating in the site lead in Cambridge, MA for the therapeutic innovation unit.
Dr. Brake began her career as a research scientist at the Western Australian Institute for Medical Research and Woden Valley Hospital. She holds a Ph.D. in molecular biology and biochemistry from the University of Western Australia.